Mayo Clinic researchers have developed a promising way to deliver treatment directly to cholangiocarcinoma tumors, a rare and aggressive bile duct cancer with limited treatment options, using milk-derived nanoparticles that act like guided delivery vehicles. The study points to a potential targeted genetic therapy designed to attack cancer cells while sparing healthy tissue.
Pairing a next-generation immunotherapy with standard hormone therapy before surgery may help overcome a long-standing barrier in early-stage prostate cancer treatment, according to a Mayo Clinic-led study.
